Brian Nowosielski

Using the PRIME program’s framework, researchers explore a digital-health and pharmacy-based lifestyle intervention for improving risk factors among patients with prediabetes.

With the federal government continuing its reconsideration of vaccine guidelines in the US, Jeff Goad, PharmD, MPH, explains what it means for community pharmacies.

In a reversal of its refusal-to-file letter issued last week, the FDA decides to move forward with Moderna’s mRNA flu vaccine developments.

Amid common patient threats stemming from severe hypoglycemia, researchers explore how proactive pharmacist outreach can translate to safer prescribing regimens for patients with diabetes.

In this episode, Natalie DiPietro Mager, PharmD, PhD, MPH, chats with Laney Poye, the director of marketing and communications at the Preeclampsia Foundation.

Jeff Goad, PharmD, MPH, joins Drug Topics to discuss potential COVID-19 vaccine removal and what it could mean for the future of mRNA vaccine technology.

Positive phase 3 data from its KALOS and LOGOS trials show the efficacy and safety of Breztri compared with 2 additional therapies.

Through a mathematical model used to assess asthma dynamics, researchers explore how active smoking can impact disease outcomes.

Jeff Goad, PharmD, MPH, president of the NFID, discusses the nuances behind COVID-19 vaccine updates and what it can mean for patients and pharmacies alike.

In a move that comes as a surprise to Moderna and various vaccine experts, the FDA continues its skeptic exploration of mRNA vaccine technology.

Amid evolving standards of care in the management of diabetes, researchers explore the role of pharmacists in facilitating continuous glucose monitoring education.

As the pharmacy industry seemingly transforms in real-time, expert pharmacists and digital health experts explain how DTP models are paving a new path for drug distribution.

In their continued fight against major health care corporations, Senators Elizabeth Warren and Josh Hawley are aiming to delink ownership among PBMs, insurers, and wholesalers.

Buchanan Ingersoll & Rooney’s Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, provide a timely legal update regarding GLP-1 distribution and compounding.

Timothy Aungst, PharmD; Ravi Patel, PharmD, MBA, MS; and Smit Patel, PharmD; provided much-needed nuance to the evolving nature of DTP pharmacy models in today’s landscape.

In what reports are calling a landmark settlement, Cigna agrees to make good on years of unfair business dealings that have affected patients and independent pharmacies.

Exploring the perspectives of health care professionals, researchers test the feasibility of the Asthma Care from Home project.

This episode explores the “uphill climb” that many leaders in the modern pharmacy landscape experience and how experts like our hosts are navigating this challenge.

Timothy Aungst, PharmD; Ravi Patel, PharmD, MBA, MS; and Smit Patel, PharmD, share their insights on the emerging direct-to-patient pharmacy model.

HIV care faces challenges from persistent stigmas and misinformation, hindering effective prevention and treatment integration into primary health care.

Anne Cassity, senior vice president of government affairs at NCPA, discusses the next moves of both PBMs and community pharmacy advocates following the signing of HR 7148.

As provisions begin rolling out over the next few years, community pharmacies will no longer be at the will of unfair reimbursement and contracting terms.

With President Trump’s signing of HR 7148, experts are now racing to get a grasp on the monumental shifts in pharmacy that will stem from this new legislation.

IBSA’s formulation of sildenafil, known as Vybrique, will hit the market in March 2026 as the first and only oral film that treats erectile dysfunction.

With infectious disease rates expected to jump as US vaccine schedules are reworked, antimicrobial stewardship programs are seeking community pharmacists.

John C. Goodman explores TrumpRx's initiatives to lower prescription drug prices, emphasizing direct-to-consumer purchasing and innovative employer strategies for savings.

Episode 7 dives into new standards of care from the American Diabetes Association and what updates are most important for pharmacists.

Through the perspectives of US health care plans and payers, researchers explore the differences in cost between single maintenance and reliever therapy and traditional therapies for treating asthma.

As lawmakers continue to deliberate on HR 7148, pharmacy law expert, Jesse Dresser, Esq, joined Drug Topics to discuss its provisions related to PBMs.

Despite a significant leap in the development of asthma therapies, depression symptoms continue to be a roadblock for improved outcomes.